AMEA
A comprehensive tissue test with an AI-powered scoring algorithm that improves PD-L1 detection.1,2*
Actionable results
in <2 weeks1†
Broad coverage
with
Medicare patients paying $0‡
Important note: Guardant360 TissueNext and Guardant Galaxy PD-L1 were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.
More comprehensive with
coverage of 498 genes1
AI-powered precision with >20% improved PD-L1 detection1,2*
AI, artificial intelligence; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death-ligand 1.
*Compared to manual pathologist interpretation in the most challenging cases of NSCLC.
†Average turnaround time from sample receipt to results.
‡For qualifying Medicare patients.